{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T11:21:37Z","timestamp":1774956097657,"version":"3.50.1"},"reference-count":70,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2009,1,29]],"date-time":"2009-01-29T00:00:00Z","timestamp":1233187200000},"content-version":"vor","delay-in-days":1308,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bpspubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["British J Pharmacology"],"published-print":{"date-parts":[[2005,7]]},"abstract":"<jats:p>\n<jats:list list-type=\"explicit-label\">\n<jats:list-item><jats:p>Tachykinin receptor agonists and antagonists were microinjected into the ventral tegmental area (VTA) to study the relative participation of the three tachykinin receptors in cardiovascular regulation in freely behaving rat.<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>Selective agonists (1\u2013100\u2003pmol) for NK<jats:sub>1<\/jats:sub> ([Sar<jats:sup>9<\/jats:sup>, Met (O<jats:sub>2<\/jats:sub>)<jats:sup>11<\/jats:sup>]SP), NK<jats:sub>2<\/jats:sub> ([<jats:italic>\u03b2<\/jats:italic>\u2010Ala<jats:sup>8<\/jats:sup>]NKA (4\u201310)) and NK<jats:sub>3<\/jats:sub> (senktide) receptors evoked increases in blood pressure, heart rate (HR) along with behavioural manifestations (face washing, sniffing, head scratching, rearing, wet dog shake). At 1\u2003pmol, NK<jats:sub>1<\/jats:sub> and NK<jats:sub>3<\/jats:sub> agonists did not affect behaviour and blood pressure but only HR.<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>Tachykinin agonists\u2010induced cardiovascular responses were selectively and reversibly blocked by the prior injection of antagonists for NK<jats:sub>1<\/jats:sub> receptors (LY 303870 ((<jats:italic>R<\/jats:italic>)\u20101\u2010[<jats:italic>N<\/jats:italic>\u2010(2\u2010methoxybenzyl)acetylamino]\u20103\u2010(1H\u2010indol\u20103\u2010yl)\u20102\u2010[<jats:italic>N<\/jats:italic>\u2010(2\u2010(4\u2010(piperidin\u20101\u2010yl)piperidin\u20101\u2010yl)acetyl)amino]propane), 5\u2003nmol), NK<jats:sub>2<\/jats:sub> receptors (SR 48968 ([(<jats:italic>S<\/jats:italic>)\u2010<jats:italic>N<\/jats:italic>\u2010methyl\u2010<jats:italic>N<\/jats:italic>\u2010[4\u2010acetylamino\u20104\u2010phenylpiperidino\u20102\u2010(3,4\u2010dichlorophenyl)butyl]benzamide]), 250\u2003pmol) and NK<jats:sub>3<\/jats:sub> receptors (SB 235375 ((\u2212)\u2010(<jats:italic>S<\/jats:italic>)\u2010<jats:italic>N<\/jats:italic>\u2010(<jats:italic>\u03b1<\/jats:italic>\u2010ethylbenzyl)\u20103\u2010(carboxymethoxy)\u20102\u2010phenylquinoline\u20104\u2010carboxamide), 25\u2003nmol). With the exception of the NK<jats:sub>2<\/jats:sub> agonist, most behavioural effects were also blocked by antagonists.<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>Tachykinin agonists\u2010induced cardiovascular responses were inhibited by intravenous (i.v.) treatments with antagonists for D<jats:sub>1<\/jats:sub> dopamine receptor (SCH23390, 0.2\u2003mg\u2003kg<jats:sup>\u22121<\/jats:sup>) and <jats:italic>\u03b2<\/jats:italic><jats:sub>1<\/jats:sub>\u2010adrenoceptor (atenolol, 5\u2003mg\u2003kg<jats:sup>\u22121<\/jats:sup>) but not for D<jats:sub>2<\/jats:sub> dopamine receptor (raclopride, 0.16\u2003mg\u2003kg<jats:sup>\u22121<\/jats:sup>). Behavioural responses were blocked by SCH23390 only.<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>The present study provides the first pharmacological evidence that the three tachykinin receptors in the rat VTA can affect the autonomic control of blood pressure and HR by increasing midbrain dopaminergic transmission. This mechanism may be involved in the coordination of behavioural and cardiovascular responses to stress and noxious stimulation.<\/jats:p><\/jats:list-item>\n<\/jats:list>\n<\/jats:p><jats:p><jats:italic>British Journal of Pharmacology<\/jats:italic> (2005) <jats:bold>145<\/jats:bold>, 712\u2013727. doi:<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"doi\" xlink:href=\"10.1038\/sj.bjp.0706249\">10.1038\/sj.bjp.0706249<\/jats:ext-link><\/jats:p>","DOI":"10.1038\/sj.bjp.0706249","type":"journal-article","created":{"date-parts":[[2005,5,16]],"date-time":"2005-05-16T08:17:43Z","timestamp":1116231463000},"page":"712-727","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["The ventral tegmental area as a putative target for tachykinins in cardiovascular regulation"],"prefix":"10.1111","volume":"145","author":[{"given":"Kathleen","family":"Deschamps","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R\u00e9jean","family":"Couture","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,1,29]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-291X(05)80041-5"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/0165-1838(89)90084-2"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0031-9384(98)00246-7"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(86)90097-1"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(89)90523-4"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0702620"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0701435"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-8993(97)01062-7"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3940(94)90068-X"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(95)00967-X"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1139\/y95-123"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(78)90484-5"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1139\/y95-122"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/0196-9781(85)90143-3"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9861(19960108)364:2<290::AID-CNE8>3.0.CO;2-0"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(82)90777-6"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(86)90667-0"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(86)90691-8"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-4328(05)80314-6"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/0143-4179(91)90141-5"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(86)91087-5"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(92)90352-P"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-2396(20000315)35:4<281::AID-SYN6>3.0.CO;2-A"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-2396(199812)30:4<362::AID-SYN3>3.0.CO;2-W"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/0165-0270(82)90036-X"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.300.1.314"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/35094560"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(91)90727-D"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(94)90515-0"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(92)90485-M"},{"key":"e_1_2_8_32_1","first-page":"774","article-title":"LY303870, a centrally active neurokinin\u20101 antagonist with a long duration of action","volume":"280","author":"IYENGAR S.","year":"1997","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3940(85)90498-7"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.2002.00828.x"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3940(79)90018-1"},{"key":"e_1_2_8_36_1","doi-asserted-by":"crossref","first-page":"H2549","DOI":"10.1152\/ajpheart.1997.273.6.H2549","article-title":"Cardiovascular depressor responses to stimulation of substantia nigra and ventral tegmental area","volume":"42","author":"KIROUAC G.J.","year":"1997","journal-title":"Am. J. Physiol. (Heart Circ. Physiol.)"},{"key":"e_1_2_8_37_1","first-page":"R1998","article-title":"Cardiovascular afferent inputs to ventral tegmental area","volume":"272","author":"KIROUAC G.J.","year":"1997","journal-title":"Am. J. Physiol."},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/0306-4522(93)90188-L"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0028-3908(00)00149-0"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.1991.71.1.155"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-8993(02)02476-9"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0705042"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0704401"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4522(97)00327-8"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0143-4179(98)90075-0"},{"key":"e_1_2_8_46_1","first-page":"167","article-title":"S 18126 ([2\u2010[4\u2010(2, 3\u2010dihydrobenzo[1, 4]dioxin\u20106\u2010yl)piperazin\u20101\u2010yl methyl]indan\u20102\u2010yl]), a potent, selective and competitive antagonist at dopamine D4 receptors: an in vitro and in vivo comparison with L 745, 870 (3\u2010(4\u2010[4\u2010chlorophenyl]piperazin\u20101\u2010yl)methyl\u20101H\u2010pyrrolo[2, 3b]pyridine) and raclopride","volume":"287","author":"MILLAN M.J.","year":"1998","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.ne.14.030191.001011"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/0165-0173(87)90011-7"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(92)90251-X"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M209532200"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1994.tb13058.x"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/0165-6147(88)90013-2"},{"key":"e_1_2_8_53_1","first-page":"195","volume-title":"Handbook of Chemical Neuroanatomy","author":"RIBEIRO\u2010DA\u2010SILVA A.","year":"2000"},{"key":"e_1_2_8_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/0196-9781(89)90148-4"},{"key":"e_1_2_8_55_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.2001.00633.x"},{"key":"e_1_2_8_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-8993(01)03402-3"},{"key":"e_1_2_8_57_1","first-page":"1","article-title":"Injection of 6\u2010hydroxydopamine into the ventral tegmental area suppresses the increase in arterial pressure during REM sleep in the rat","volume":"2","author":"SEI H.","year":"1999","journal-title":"Sleep Res. Online"},{"key":"e_1_2_8_58_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9861(19960826)372:3<395::AID-CNE5>3.0.CO;2-Y"},{"key":"e_1_2_8_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(90)91015-9"},{"key":"e_1_2_8_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/0361-9230(82)90145-9"},{"key":"e_1_2_8_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-8993(00)02905-X"},{"key":"e_1_2_8_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(90)91662-Z"},{"key":"e_1_2_8_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3940(90)90779-9"},{"key":"e_1_2_8_64_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1992.tb14518.x"},{"key":"e_1_2_8_65_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.63.4.812"},{"key":"e_1_2_8_66_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1681.1997.tb02129.x"},{"key":"e_1_2_8_67_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1681.1998.tb02273.x"},{"key":"e_1_2_8_68_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0702982"},{"key":"e_1_2_8_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-0102(99)00037-1"},{"key":"e_1_2_8_70_1","doi-asserted-by":"publisher","DOI":"10.1002\/cne.902720107"},{"key":"e_1_2_8_71_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1986.tb04571.x"}],"container-title":["British Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1038%2Fsj.bjp.0706249","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1038%2Fsj.bjp.0706249","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1038\/sj.bjp.0706249","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T00:53:06Z","timestamp":1697158386000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1038\/sj.bjp.0706249"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,7]]},"references-count":70,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2005,7]]}},"alternative-id":["10.1038\/sj.bjp.0706249"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjp.0706249","archive":["Portico"],"relation":{},"ISSN":["0007-1188","1476-5381"],"issn-type":[{"value":"0007-1188","type":"print"},{"value":"1476-5381","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,7]]},"assertion":[{"value":"2009-01-29","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}